Vertex Pharmaceuticals recently presented updated interim data at the 2025 ASN Kidney Week, revealing significant proteinuria ...

PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial ...

Vertex Pharmaceuticals’ povetacicept – This BAFF/APRIL dual-pathway inhibitor has emerged as a strong contender in the MN pipeline. Nephrologists view the differentiated mechanism as addressing core ...

New research reveals that contrary to conventional belief, primary glomerular diseases are not necessarily benign for ...

Vertex Pharmaceuticals (VRTX) announced updated data for povetacicept in IgA nephropathy and primary membranous nephropathy from the ongoing ...

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person at American Society of Nephrology Kidney Week 2025 November 5–9.

New research reveals that contrary toconventional belief, primary glomerular diseases are not necessarily benign for children ...

Primary glomerular diseases in children and young adults can cause rapid kidney function decline, increasing lifetime risk of ...

Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights ...

Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% ...